BAYRY Stock - Bayer AG
Unlock GoAI Insights for BAYRY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $46.61B | $47.64B | $50.74B | $44.08B | $41.40B |
| Gross Profit | $25.34B | $27.89B | $30.87B | $27.27B | $22.26B |
| Gross Margin | 54.4% | 58.5% | 60.8% | 61.9% | 53.8% |
| Operating Income | $3.33B | $-150,000,000 | $6.26B | $6.97B | $-2,939,000,000 |
| Net Income | $-2,552,000,000 | $-2,941,000,000 | $4.15B | $1.00B | $-15,561,000,000 |
| Net Margin | -5.5% | -6.2% | 8.2% | 2.3% | -37.6% |
| EPS | $-0.65 | $-0.75 | $1.06 | $0.26 | $-3.96 |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2025 | JP Morgan | Upgrade | Overweight | - |
| December 3rd 2025 | Morgan Stanley | Upgrade | Overweight | - |
| June 11th 2025 | Kepler | Upgrade | Buy | - |
| September 6th 2024 | BofA Securities | Upgrade | Neutral | - |
| May 30th 2024 | Goldman | Initiation | Neutral | - |
| March 7th 2024 | Bernstein | Downgrade | Market Perform | - |
| February 29th 2024 | Citigroup | Downgrade | Neutral | - |
| January 30th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| December 18th 2023 | HSBC Securities | Downgrade | Reduce | - |
| December 4th 2023 | UBS | Downgrade | Neutral | - |
| November 21st 2023 | Jefferies | Downgrade | Hold | - |
| November 14th 2023 | Deutsche Bank | Downgrade | Hold | - |
| October 10th 2023 | HSBC Securities | Upgrade | Hold | - |
| September 25th 2023 | Redburn Atlantic | Downgrade | Neutral | - |
| August 16th 2023 | Berenberg | Downgrade | Hold | - |
Earnings History & Surprises
BAYRYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $0.17 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.13 | $0.17 | +30.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.25 | $0.35 | +40.0% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $0.28 | $0.28 | 0.0% | = MET |
Q4 2024 | Dec 31, 2024 | — | $-0.09 | — | — |
Q4 2024 | Nov 12, 2024 | $0.17 | $0.07 | -58.8% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $0.25 | $0.25 | 0.0% | = MET |
Q2 2024 | May 14, 2024 | $0.46 | $0.77 | +68.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.45 | $0.50 | +11.1% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.28 | $0.10 | -64.3% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.39 | $0.33 | -15.4% | ✗ MISS |
Q2 2023 | May 11, 2023 | $0.55 | $0.79 | +43.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.32 | $0.34 | +6.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.30 | $0.29 | -3.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.46 | $0.51 | +10.9% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.77 | $0.99 | +28.6% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $0.33 | — | — |
Q4 2021 | Nov 9, 2021 | $0.30 | $0.31 | +3.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.47 | $0.48 | +2.1% | ✓ BEAT |
Latest News
Evotec And Bayer Kidney Disease Collaboration Advances SEMA3A Monoclonal Antibody Program Into Phase 2 Clinical Development
📈 PositiveBayer surges after Trump administration backs Supreme Court review in Roundup case
📈 PositiveBayer On Monday Confirmed U.S. Solicitor General's Support For Supreme Court Review Of Roundup Litigation
📈 PositiveBayer stock sees its best day in 17 years
📈 PositiveDaré Bioscience Regains Full Rights To Ovaprene As Bayer Terminates License Agreement
📉 NegativeBristol-Myers Squibb shares are trading higher. Strength may be due to investor optimism after Bayer announced topline results from its Phase 3 OCEANIC-STROKE study.
📈 PositiveBayer Raises FY2025 Sales Guidance from $52.154B-$54.422B to $53.784B-$56.123B
📈 PositiveBayer Q3 Adj. EPS $0.17 Up From $0.07 YoY, Sales $11.295B Beat $10.930B Estimate
📈 PositiveGinkgo Bioworks Extends Its Multi-Year Partnership With Bayer To Continue Developing Biological Products For Agriculture, Focusing On Microbial Nitrogen Fixation
📈 Positive'IPG Wins Bayer's $720M Global Consumer Health Account '- Adweek
📈 PositiveBayer drops as core businesses underperform in Q2
📉 NegativeBayer hits highest since October after winning upgrades at HSBC, Kepler Cheuvreux
📈 PositiveBayer raised to Buy at Goldman after hitting bottom of negative earnings revision cycle
📈 PositiveBayer plunges as Roundup ingredient glyphosate reportedly singled out in RFK's upcoming report
📉 NegativeFrequently Asked Questions about BAYRY
What is BAYRY's current stock price?
What is the analyst price target for BAYRY?
What sector is Bayer AG in?
What is BAYRY's market cap?
Does BAYRY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BAYRY for comparison